Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT STEP trial of first-line ibrutinib + venetoclax with obinutuzumab intensification in CLL/SLL
2019-002528-34Phase 2Active
- Sponsor
- HOVON
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoint: Bone marrow undetectable minimal residual disease complete remission at 3 months after intensification. Started Aug 2020; status: active.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-002528-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002528-34.